Kite Readies for CAR-T Therapy Submission and Commercial Launch; Shares Undervalued
Kite Pharma’s positive pipeline development in the third quarter is starting to reveal a light at the end of the tunnel. The company is positioned to launch the first CAR-T treatment in the market, ahead of competitors at the end of 2017 or early 2018, thanks to the strong efficacy data shown in its pivotal ZUMA-1 trial. Given that the expected approval of Kite’s CAR-T therapy KTE-C19 remains on track for the end of 2017, we do not plan on changing our $68 per share fair value estimate at this t...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.